Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 7707 results

  1. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative

    Diagnostics guidance
    Published
    2 October 2013
    View recommendations

    Sections for DG11

  2. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (MTG9)

    Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.

    Medical technologies guidance
    Last updated
    19 July 2022
    View recommendations

    Sections for MTG9

  3. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (DG52)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers

    Diagnostics guidance
    Published
    24 May 2023
    View recommendations

    Sections for DG52

  4. MRI fusion biopsy systems for diagnosing prostate cancer (DG53)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer

    Diagnostics guidance
    Published
    24 May 2023
    View recommendations

    Sections for DG53

  5. Transperineal biopsy for diagnosing prostate cancer (DG54)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer

    Diagnostics guidance
    Published
    1 June 2023
    View recommendations

    Sections for DG54

  6. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

    Awaiting development [GID-TA10519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

    Awaiting development [GID-TA10909] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...

    Technology appraisal guidance
    Topic selection

  9. Tocilizumab for treating systemic sclerosis (ID1396)

    Awaiting development [GID-TA10346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development [GID-TA10453] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. OrganOx metra for liver transplant [ID5116]

    In development [GID-TA11035] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...

    Technology appraisal guidance
    Topic selection

  13. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development [GID-HST10022] Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  14. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. ...

    Technology appraisal guidance
    Topic selection

  15. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development [GID-TA10279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development